NCT04061811View on ClinicalTrials.gov

Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients

CompletedOBSERVATIONAL

Enrollment

153

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions

Heart FailureEnd Stage Renal Disease

Interventions

DIAGNOSTIC_TEST

Diagnostic biomarker study

Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.

Trial Locations (2)

30175

Hannover Medical School, Hanover

Unknown

Inserm Umr S-942, Paris

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

F-CRIN

UNKNOWN

lead

Hannover Medical School

OTHER

NCT04061811 - Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients | Biotech Hunter | Biotech Hunter